Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Ipsos
  6. News
  7. Summary
    IPS   FR0000073298


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ipsos : phRMA - Growing trend, Increased vaccine confidence

01/29/2021 | 06:02am EDT

According to researchers writing in The Lancet, we need a majority of Americans to have the confidence to get vaccinated for COVID-19 if we are going to be effective in moving the United States toward population-level control of viral spread.

As Dr. Anthony Fauci has noted, 'If you have a vaccine that is highly effective and not enough people get vaccinated, you're not going to realize the full, important effect of having a vaccine.'

The good news is a growing majority of Americans are expressing COVID-19 vaccine readiness. The increase in confidence follows news about the first two COVID-19 vaccines confirmed with over 95% efficacy and the subsequent emergency use authorizations (EUA) granted by the U.S. Food and Drug Administration (FDA) for administration of the vaccines to patients.

Recent opinion research conducted by PhRMA[1], Gallup, Ipsos and others confirms this trend, with almost two-thirds of the U.S. public expressing willingness to get a vaccine if one were available to them today. Our most recent tracking survey, conducted with Morning Consult, shows 65% readiness for a vaccine, a 5-point increase from October. Gallup reports the same percentage and Ipsos shows an 8-point confidence boost of late, with 60% overall readiness. The PhRMA poll noted above also shows an 18-point increase in the number of Americans who say they will take a vaccine 'right away' (45%, up from 27%).

Another big story in Gallup's vaccine confidence numbers is the recent change by key subgroups. We have long seen significant differences in attitudes by gender, race, income, education and political party affiliation. Notably, the confidence gap has widened between Democrats (83%, up 8 points since December) and Republicans (45%, down 5 points), as well as between those with a 4-year college degree (77%, up 9 points) and those without (60%, down 1 point). The gender and race gaps, however, have closed over the past month to single digits (3 points and 5 points, respectively).

In line with these numbers is a growing appreciation for the significant value COVID-19 vaccines provide. In our survey noted above, 72% of American voters agree (39% strongly) that vaccines are key to ending the pandemic, and the public widely recognizes that vaccines will not only help save lives (62% likely to happen after a vaccination becomes available) but also restore core aspects of our day-to-day living, including the re-opening of schools (62% likely), businesses (61% likely) and restaurants (58% likely). Recent public polling reinforces theses trend with the Axios-Ipsos Coronavirus Index showing new urgency in plans to be vaccinated, and Pew Research linking intent to be vaccinated to confidence in biopharmaceutical research and development (R&D).

As the biopharmaceutical industry continues to study new and ongoing vaccine candidates through clinical trials, continued education will be critical to recognizing the benefits of the vaccines. We also know there continues to be several important questions from the public about these vaccines. It is critical all health care stakeholders come together to share open, honest and transparent information to help instill confidence.


Tel: (202) 835-3400

Web: www.PhRMA.org

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about IPSOS
09/23IPSOS : Vaccines Europe - Five things COVID could learn from Invasive Meningococcal Diseas..
09/21GENERAL MILLS : May Not See Fiscal First-Quarter 'Surprises' Following Updated Fiscal 2022..
09/18Germany's Laschet says trusts ECB to keep inflation in check
09/16IPSOS : To Buy Software, Digital Services Provider
09/15IPSOS : acquires Infotools and further upscales digital capabilities to fuel growth
09/15Ipsos SA entered into an agreement to acquire Infotools.
09/14IPSOS : North America CEO Steps Down; Successor Named
09/14IPSOS : Appointment of Lorenzo Larini as Chief Executive Officer, Ipsos in North America
09/14Ipsos Announces Appointment of Lorenzo Larini as Chief Executive Officer, Ipsos in Nort..
09/09Canada PM Trudeau portrays main rival as weak in key leaders' debate
More news
Sales 2021 2 120 M 2 484 M 2 484 M
Net income 2021 155 M 181 M 181 M
Net Debt 2021 420 M 492 M 492 M
P/E ratio 2021 12,4x
Yield 2021 2,45%
Capitalization 1 895 M 2 219 M 2 220 M
EV / Sales 2021 1,09x
EV / Sales 2022 1,00x
Nbr of Employees 17 640
Free-Float 85,4%
Duration : Period :
Ipsos Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSOS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 6
Last Close Price 42,75 €
Average target price 46,13 €
Spread / Average Target 7,91%
EPS Revisions
Managers and Directors
Didier Michel Truchot Chairman, President & Chief Executive Officer
Laurence Stoclet Chief Financial Officer, Director & Deputy CEO
Neville Rademeyer Global Chief Information Officer
Patrick Artus Independent Director
Dupont-Madinier Mary Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IPSOS54.89%2 229
WPP PLC24.63%16 154
OMNICOM GROUP INC.16.15%15 900